Lab Head: Nick Leslie Institute of Biological Chemistry, Biophysics and Bioengineering

Selected Publications

For a more complete list look here



Gupta A and Leslie NR (2016). Controlling PTEN (Phosphatase and Tensin Homolog) Stability: a Dominant Role for Lysine 66. JBC, epub 12th July 2016
Leslie NR and Longy M (2016). Inherited PTEN mutations and the prediction of phenotype. Sem Cell Dev Biol., 52, 30-38


Spinelli L, Black FM, Berg JN, Eickholt BJ and Leslie NR (2015). Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes. J. Med. Genet. 52, 128-134


Leslie NR and den Hertog J (2014). Mutant PTEN in Cancer: Worse Than Nothing. Cell, 157, p527-9
Spinelli L, Lindsay Y and Leslie NR (2014). PTEN inhibitors: an evaluation of current compounds. Adv. Biol. Regul. 57, 102-11
Hawley SA, Ross FA, Gowans GJ, Tibarewal P, Leslie NR and Hardie DG (2014). Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells. Biochem J. 459, 275-87


Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Wildund HR, Ryu B, Alani R, Dutton-Regester K, Goding CR, Hayward NK, Wei W and Cui R. (2013). MC1R is a Potent Regulator of PTEN after UV Exposure in Melanocytes. Molecular Cell, 51, 409-422.
McGuire VA, Gray A, Monk CE, Santos SG, Lee K, Aubareda A, Crowe J, Ronkina N, Schwermann J, Batty IH, Leslie NR, Dean JL, O'Keefe SJ, Boothby M, Gaestel M and Arthur JS (2013). Crosstalk between the Akt and p38α pathways in macrophages downstream of TLR signalling. Mol Cell Biol. Epub 26/8/13
Leslie NR and Brunton VG (2013). Where is PTEN? Science. 341, p355-6
Kreis P, Hendricusdottir R, Kay L, Papageorgiou IE, van Diepen M, Mack T, Ryves J, Harwood A, Leslie NR, Kann O, Parsons M, Eickholt BJ (2013). Phosphorylation of the Actin Binding Protein Drebrin at S647 Is Regulated by Neuronal Activity and PTEN. PLoS ONE, Epub 5/8/13
Dieterle AM, Böhler P, Keppeler H, Alers S, Berleth N, Drießen S, Hieke N, Pietkiewicz S, Löffler AS, Peter C, Gray A, Leslie NR, Shinohara H, Kurosaki T, Engelke M, Wienands J, Bonin M, Wesselborg S, Stork B (2013). PDK1 controls upstream PI3K expression and PIP3 generation. Oncogene, Epub 29/7/132
Koh A, Lee MN, Yang YR, Jeong H, Ghim J, Noh J, Kim J, Ryu D, Park S, Song P, Koo SH, Leslie NR, Berggren PO, Choi JH, Suh PG, Ryu SH (2013). C1-Ten is a Protein Tyrosine Phosphatase of IRS-1, Regulating IRS-1 Stability and Muscle Atrophy. Mol Cell Biol. Epub 11/2/13
Berglund, FM, Weerasinghe, NR, Davidson, L, Lim, JC, Eickholt, BJ and Leslie NR (2012). Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110a/PIK3CA but not by HER2 or mutant AKT1. Oncogene, Epub 22/10/12


Dixon MJ, Gray A, Schenning M, Agacan M, Tempel W, Tong Y, Nedyalkova L, Park HW, Leslie NR, van Aalten DM, Downes CP, Batty IH. (2012). IQGAP proteins reveal an atypical phosphoinositide (aPI) binding domain with a pseudo C2 domain fold. J Biol Chem. Epub 5/4/12
Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A, Perera NM, Davidson L, Barton GJ, and Leslie NR (2012). PTEN protein phosphatase activity correlates with control of invasion, gene expression and tumour suppression, but not AKT. Science Signaling, 5, ra18


Dixon MJ, Gray A, Boisvert FM, Agacan M, Morrice NA, Gourlay R, Leslie NR, Downes CP and Batty IH (2011). A Screen for novel phosphoinositide 3-kinase effector proteins. Mol. Cell. Proteomics. Epub 24/1/11
PubMed ink
Leslie NR and Foti M (2011). Non-genomic loss of PTEN in cancer: not in my genes. Trends in Pharmacological Sciences. 32, 131-140
PubMed link
Leslie NR, Dixon MJ, Schenning M, Gray A and Batty IH (2012). Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. Adv Enzyme Regul. 52, 205-213
PubMed link


Ellis IR, Jones SJ, Lindsay Y, Ohe G, Schor AM, Schor SL and Leslie NR (2010). Migration Stimulating Factor (MSF) promotes fibroblast migration by inhibiting AKT. Cell. Signalling 22, 1655-1659
PubMed link
Maccario H, Perera NM, Gray A, Downes CP and Leslie NR (2010). Ubiquitination of PTEN inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. J. Biol. Chem. 285, 12620-8
PubMed link
Davidson L, Maccario H, Perera NM, Yang X, Spinelli L, Tibarewal P, Glancy B, Gray A, Weijer CJ, Downes CP and Leslie NR (2010). Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Oncogene 29, 687-97
PubMed link
Leslie NR, Spinelli L, Tibarewal P, Zilidis G, Weerasinghe N, Lim JC, Maccario H and Downes CP (2010). Indirect mechanisms of carcinogenesis via downregulation of PTEN function. Adv Enzyme Regul. Epub 4/11/09.
Moult PR, Cross A, Santos SD, Carvalho AL, Lindsay Y, Connolly CN, Irving AJ, Leslie NR and Harvey J (2010). Leptin regulates AMPA receptor trafficking via PTEN inhibition. J Neurosci. 30, 4088-101


Leslie NR (2009). P-REX2a Driving Tumorigenesis by PTEN Inhibition. Science Signaling. 2, pe68
Van Diepen M, Parsons M, Downes CP, Leslie NR, Hindges R and Eickholt BJ (2009). MyosinV controls PTEN function and neuronal cell size. Nat. Cell Biol. 11, 1191-6
Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C and Neumann CA (2009). Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 28, 1505-17
Leslie NR, Maccario H, Spinelli L and Davidson L (2009). The significance of PTEN's protein phosphatase activity. Advances in Enzyme Regulation 49, 190-6


Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA and Barata JT (2008). PTEN Non-deletional Inactivation and Hyperactivation of PI3K/Akt Pathway Regulate Primary T-Cell Leukemia Viability. J. Clin. Invest. 118, 3762-74
Leslie NR, Batty IH, Maccario H, Davidson L and Downes CP (2008). Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 27, 5464-5476
Green CJ, Göransson O, Kular GS, Leslie NR, Gray A, Alessi DR, Sakamoto K and Hundal HS (2008). Use of Akti and a drug-resistant mutant validates a critical role for PKB/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J Biol Chem. 283, 27653-67


Maccario H, Perera NM, Davidson L, Downes CP and Leslie NR (2007). PTEN is destabilised by phosphorylation on threonine 366. Biochem. J. 405, 439-444
Lackey J, Barnett J, Davidson L, Batty IH, Leslie NR and Downes CP (2007). Loss of PTEN selectively desensitises upstream IGF1 and insulin signalling. Oncogene 26, 7132-42
Ross SR, Lindsay Y, Safrany ST, Lorenzo O, Villa F, Toth R, Clague MJ, Downes CP and Leslie NR (2007). Differential redox regulation within the PTP superfamily. Cellular Signalling 19, 1521-1530
Leslie NR, Yang X, Downes CP and Weijer CJ (2007). PtdIns(3,4,5)P3-dependent and -independent roles for PTEN in the control of cell migration. Current Biol. 17, 115-125


Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A, Lucocq J and Downes CP (2006). Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J. Cell Sci. 119, 5160-5168
Ning K, Miller LC, Laidlaw HA, Burgess LA, Perera NM, Downes CP, Leslie NR and Ashford ML (2006). A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells. EMBO J., 25, 2377-2387
Leslie NR (2006). The redox regulation of PI 3-kinase dependent signalling. Antioxid. Redox Signal., 8, 1765-1774


Bayascas JR, Leslie NR, Parsons R, Fleming S and Alessi DR (2005) Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN +/- mice. Current Biol., 15, 1839-1846
Leslie NR, Yang X, Downes CP and Weijer CJ (2005). The regulation of cell migration by PTEN. Biochem. Soc. Trans., 33, 1507-1508


Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol, 166, 213-223
Leslie NR and Downes CP (2004). PTEN function: how normal cells control it and tumour cells lose it. Biochem. J., 382, 1-11
Spruce BA, Campbell LA, Mc Tavish N, Cooper MA, Appleyard MVL, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM and Eccles S (2004). Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 64, 4875-4886
Walker SM, Leslie NR, Perera NM, Batty IH, and Downes CP (2004). The tumour suppressor function of PTEN requires an N-terminal lipid binding motif. Biochem J. 379, 301-307
Leslie NR and Downes CP (2004). Phosphoinositide dependent protein kinases. In 'The Encyclopedia of Biological Chemistry', eds Lennarz WJ and Lane MD, (Elsevier Science).


Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A and Downes CP (2003). Redox regulation of PI 3-kinase signaling via inactivation of PTEN. EMBO J., 22, 5501-5510


Leslie NR and Downes CP (2002). PTEN: the down side of PI-3 kinase signalling. Cell Signal., 14, 285-295


Walker SM, Downes CP and Leslie NR (2001). TPIP: a novel phosphoinositide 3-phosphatase. Biochem J. 360, 277-283
Leslie NR, Bennett D, Gray A, Pass I, Hoang-Xuan K and Downes CP (2001). Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem. J. 357, 427-435
Leslie NR, Biondi RM and Alessi DR (2001). Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem. Rev., 101, 2365-2380


Leslie NR, Gray A, Pass I, Orchiston EA and Downes CP (2000). Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase. Biochem. J., 346, 827-833